Effectiveness of Upadacitinib for Patients With Acute Severe Ulcerative Colitis: A Multicenter Experience

• Published in: The American journal of gastroenterology Vol. 119; no. 7; pp. 1421 - 1425
• Main Authors: Berinstein, Jeffrey A, Karl, Taylor, Patel, Anish, Dolinger, Michael, Barrett, Terrence A, Ahmed, Waseem, Click, Ben, Steiner, Calen A, Dulaney, David, Levine, Jake, Hassan, Syed Adeel, Perry, Courtney, Flomenhoft, Deborah, Ungaro, Ryan C, Berinstein, Elliot M, Sheehan, Jessica, Cohen-Mekelburg, Shirley, Regal, Randolph E, Stidham, Ryan W, Bishu, Shrinivas, Colombel, Jean-Frederic, Higgins, Peter D R
• Format: Journal Article
• Language: English
• Published: United States Wolters Kluwer Health Medical Research, Lippincott Williams & Wilkins 01.07.2024
• Subjects: Endoscopy; Hospitals; Inflammatory bowel disease; Patients; Remission (Medicine); Steroids; Systematic review; Tumor necrosis factor-TNF
• ISSN: 0002-9270; 1572-0241; 1572-0241
• DOI: 10.14309/ajg.0000000000002674

A significant proportion of patients with acute severe ulcerative colitis (ASUC) require colectomy. Patients with ASUC treated with upadacitinib and intravenous corticosteroids at 5 hospitals are presented. The primary outcome was 90-day colectomy rate. Secondary outcomes included frequency of steroid-free clinical remission, adverse events, and all-cause readmissions. Of the 25 patients with ASUC treated with upadacitinib, 6 (24%) patients underwent colectomy, 15 (83%) of the 18 patients with available data and who did not undergo colectomy experienced steroid-free clinical remission (1 patient did not have complete data), 1 (4%) patient experienced a venous thromboembolic event, while 5 (20%) patients were readmitted. Upadacitinib along with intravenous corticosteroids may be an effective treatment for ASUC.